Search results for "MOTH"

showing 10 items of 2617 documents

Revision of Hermadion Kinberg, 1856, with a redescription of Hermadion magalhaensi Kinberg, 1856, Adyte hyalina (G.O. Sars, 1873) n. comb. and Neopol…

2010

Examination of all species previously referred to the genus Hermadion revealed that the type species, H. magalhaensi Kinberg, 1856, is the only valid species in the genus. H. magalhaensi is redescribed and its synonymy with Hermadion longicirratus Kinberg, 1856, Hermadion kerguelensis McIntosh, 1885, and Lagisca laevis Hartmann-Schroder, 1962, is discussed. The generic attribution of 12 species that had already been moved from Hermadion to other genera by earlier authors is confirmed. Following our re-examination four species are moved to other genera: Harmothoe ornatus (Hartman, 1967) n. comb., Harmothoe africanus (Hartman, 1974) n. comb., Adyte hyalina (G.O. Sars, 1873) n. comb., and Neop…

biologyAnnelidaZoologyIdentification keyPolychaetaBiodiversitybiology.organism_classificationNeopolynoeType speciesPhyllodocidaGenusAnimaliaAnimal Science and ZoologyTaxonomy (biology)HarmothoePolynoidaeNomen nudumPolynoidaeEcology Evolution Behavior and SystematicsTaxonomyZootaxa
researchProduct

THERMOREGULATION CONSTRAINS EFFECTIVE WARNING SIGNAL EXPRESSION

2009

Evolution of conspicuous signals may be constrained if animal coloration has nonsignaling as well as signaling functions. In aposematic wood tiger moth (Parasemia plantaginis) larvae, the size of a warning signal (orange patch on black body) varies phenotypically and genetically. Although a large warning signal is favored as an antipredator defense, we hypothesized that thermoregulation may constrain the signal size in colder habitats. To test this hypothesis, we conducted a factorial rearing experiment with two selection lines for larval coloration (small and large signal) and with two temperature manipulations (high and low temperature environment). Temperature constrained the size and br…

biologyPigmentationEcologyfungiAnimal colorationAposematismLow temperature treatmentMothsThermoregulationbiology.organism_classificationBiological EvolutionPredationTwo temperatureParasemia plantaginisLarvaPredatory BehaviorGeneticsAnimalsGrowth rateGeneral Agricultural and Biological SciencesEcology Evolution Behavior and SystematicsBody Temperature RegulationEvolution
researchProduct

A New Species ofTelenomusHaliday (Hymenoptera: Scelionidae) Associated with Egg Batches of the Pine Processionary Moth,Thaumetopoea pityocampa(Dennis…

2009

Telenomus thaumetopoeae Buhl sp. n. is described from northeastern València (Peninsular Spain) taking as starting point females parasitizing the egg-batches of the Pine Processionary Moth, Thaumetopoea pityocampa (Dennis et Schiffermüller, 1775). Its morphological affinities with the most closely related species and parasitism data are offered.

biologyThaumetopoea pityocampaParasitismNotodontidaeHymenopterabiology.organism_classificationLepidoptera genitaliaArbres Malalties i plaguesInsect ScienceBotanyBotànicaTaxonomy (biology)Pine processionary mothEcology Evolution Behavior and SystematicsScelionidaeEntomological News
researchProduct

Insecticidal activity of Vip3Aa, Vip3Ad, Vip3Ae, and Vip3Af from Bacillus thuringiensis against lepidopteran corn pests.

2012

Vip3Aa, Vip3Ad, Vip3Ae, and Vip3Af proteins from Bacillus thuringiensis were tested for their toxicity against Spodoptera frugiperda and Agrotis ipsilon. Vip3Ad was non-toxic to the two species. Vip3Ae and Vip3Af were significantly more toxic than Vip3Aa against S. frugiperda, both as protoxins and as toxins. Against A. ipsilon, Vip3Ae protoxin was more toxic than Vip3Aa and Vip3Af protoxins. Purification by metal-chelate affinity chromatography significantly affected Vip3Ae toxicity against the two insect species.

biologybusiness.industryvirusesfungiPest controlBacillus thuringiensisAgrotis ipsilonSpodopteraMothsbiology.organism_classificationMicrobiologyAffinity chromatographyBacterial ProteinsBacillus thuringiensisparasitic diseasesToxicityFall armywormAnimalsElectrophoresis Polyacrylamide GelbusinessPest Control BiologicalPolyacrylamide gel electrophoresisEcology Evolution Behavior and SystematicsJournal of invertebrate pathology
researchProduct

CCDC 831123: Experimental Crystal Structure Determination

2011

Related Article: E.Nauha, E.Kolehmainen, M.Nissinen|2011|CrystEngComm|13|6531|doi:10.1039/c1ce05730h

bis(Dimethyl (12-phenylenedicarbamothioyl)biscarbamate) sesquikis(22'-bipyridine) acetonitrile solvateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

Is the efficacy of intravescical chemotherapy influenced by cigarette smoking? Data obtained in intermediate risk non muscle invasive bladder carcino…

2011

Aim of the study To study recurrence-free rate (RFR) and recurrence-free survival (RFS) according to the smoking status in patients affected by non-muscle invasive carcinoma of the bladder (NMI-BC) treated by intravesical chemotherapy. Materials and methods Smoking status was recorded at study entry. Intravesical epirubicin was administered within 6 hours from TUR at the dose of 80 mg diluted in 50 ml of saline solution. Further adjuvant treatment in low-risk and high-risk patients was given according to physicians’ choice. The remaining patients, at intermediate risk for recurrence, were randomized between two different schemes of intravesical chemotherapy: 5 more weekly instillations (tot…

bladder cancer cigarette smoking intravesical chemotherapy
researchProduct

CHOICE OF ADJUVANT INTRAVESICAL THERAPY IN RECURRING INTERMEDIATE-RISK NMI-BC

2011

Objective: The therapeutic strategy for patients affected by intermediate risk non-muscle invasive bladder cancer (NMIBC) recurring after intravesical therapy is not definitively established. Only few studies have been published on secondline intravesical therapy. BCG is advocated when intravesical chemotherapy fails and is often repeated. On the other hand, some patients that suffer recurrence repeat intravesical chemotherapy. A retrospective analysis of 179 intermediaterisk patients submitted to second-line intravesical therapy is reported. Patients and Methods: The clinical files of patients affected by intermediate risk NMI-BC and submitted to second-line adjuvant intravesical therapy w…

bladder cancer intravesical chemotherapy BCGSettore MED/24 - Urologia
researchProduct

A prospective observational study on oral administration of Ellagic Acid and Annona Muricata in patients affected by non-muscle invasive bladder canc…

2021

Introduction: BCG and MMC shortage and Covid-19 pandemic, more recently, limit accessibility to maintenance regimen in intravesical prophylaxis against recurrence of non-muscle invasive bladder cancer (NMIBC). Ellagic acid (EA) and Annona muricata (AM) exert antitumor activity against different human tumours. An observational prospective study on the prophylactic effect of oral administration of EA+AM in patients avoiding maintenance regimen is presented. Materials and methods: Patients affected by NMIBC and not undergoing maintenance after a 6-week course of intravesical prophylaxis with MMC or BCG were entered. Tis and very high-risk tumours were excluded. After informed consent, the pati…

bladder carcinomamedicine.medical_specialtybacillus calmette-guerinmedicine.medical_treatment030232 urology & nephrologyAdministration Oralnutraceuticsintravesical instillationGastroenterologyAnnonalaw.inventionannona muricata03 medical and health sciences0302 clinical medicineAdjuvants ImmunologicRandomized controlled trialellagic acidOral administrationlawInternal medicineCytologymedicineHumansNeoplasm InvasivenessProspective StudiesProspective cohort studyPandemicsChemotherapyBladder cancermedicine.diagnostic_testSARS-CoV-2business.industryCOVID-19General MedicineCystoscopymedicine.diseaseRegimenAdministration IntravesicalUrinary Bladder Neoplasms030220 oncology & carcinogenesisBCG VaccineNeoplasm Recurrence Localbusinessannona muricata; bacillus calmette-guerin; bladder carcinoma; ellagic acid; intravesical instillation; nutraceuticsUrologia Journal
researchProduct

Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcomes at a single academic centre.

2020

INTRODUCTION: Pancreatic cancer (PC), even in the absence of metastatic disease, has a dismal prognosis. One-third of them are borderline resectable (BRPC) or locally advanced unresectable PC (LAUPC) at diagnosis. There are limited prospective data supporting the best approach on these tumours. Neoadjuvant chemotherapy (ChT) is being increasingly used in this setting. METHODS: This is a retrospective series of consecutive patients staged as BRPC or LAUPC after discussion in the multidisciplinary board (MDB) at an academic centre. All received neoadjuvant ChT, followed by chemoradiation (ChRT) in some cases, and those achieving enough downstaging had a curative-intent surgery. Descriptive da…

borderline resectableCancer Researchmedicine.medical_specialtyFOLFIRINOXmedicine.medical_treatmentpancreatic cancerNeutropeniaAdenocarcinomalcsh:RC254-282Pancreatic cancerAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective Studies1506Neoadjuvant therapyRetrospective StudiesOriginal ResearchChemotherapybusiness.industrymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslocally advanced unresectableNeoadjuvant TherapyOxaliplatinSurgeryIrinotecanPancreatic NeoplasmsFOLFIRINOXOncologyFluorouracilbusinessmedicine.drugESMO open
researchProduct

Nab-paclitaxel in pretreated metastatic breast cancer: evaluation of activity, safety, and quality of life

2019

Rossella De Luca,1 Giuseppe Profita,2 Giuseppe Cicero1 1Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy; 2Department of Surgical, Oncological and Oral Sciences, Section of Surgical, University of Palermo, Palermo, Italy Objective: Metastatic breast cancer (MBC) is an incurable disease; the treatment of this disease prolongs survival, improving the quality of life (QoL) with a balance between efficacy and toxicity of the treatment. In recent years, treatment with nab-paclitaxel has improved the already known antitumor activity of conventional paclitaxel, in terms of increased efficacy and better tolerability. The aim o…

breast cancer metastasibreast cancer metastasisoverall survivalAbraxane®Ca15.3painchemotherapyOncoTargets and TherapyOriginal ResearchOncoTargets and Therapy
researchProduct